Who are Thalidomide, Dexamethasone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abrilada, Humira, Adalimumab with methotrexate, Enbrel (etanercept), Etanercept (ETN), TNF Inhibitor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/thalidomide-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Thalidomide, Dexamethasone — Competitive Intelligence Brief

Thalidomide, Dexamethasone (Thalidomide, Dexamethasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-inflammatory, Immunomodulator. Area: Oncology.

phase 3 Anti-inflammatory, Immunomodulator TNF-alpha Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Thalidomide, Dexamethasone (Thalidomide, Dexamethasone) — Grupo de Estudos Multicentricos em Onco-Hematologia. Thalidomide inhibits the release of tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in inflammation and immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Thalidomide, Dexamethasone TARGET	Thalidomide, Dexamethasone	Grupo de Estudos Multicentricos em Onco-Hematologia	phase 3	Anti-inflammatory, Immunomodulator	TNF-alpha
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Adalimumab with methotrexate	Adalimumab with methotrexate	Pfizer	marketed	TNF-alpha inhibitor + DMARD combination	TNF-alpha; dihydrofolate reductase
Enbrel (etanercept)	Enbrel (etanercept)	Pfizer	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
Etanercept (ETN)	Etanercept (ETN)	University of Leeds	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
TNF Inhibitor	tnf-inhibitor	Pfizer	marketed	Monoclonal Antibody	TNF-alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-inflammatory, Immunomodulator class)

Grupo de Estudos Multicentricos em Onco-Hematologia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thalidomide, Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/thalidomide-dexamethasone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab